Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
227 enrolled
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
Phase 1 Terminated
13 enrolled 12 charts
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase 1 Terminated
28 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Phase 1 Terminated
4 enrolled
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Phase 1 Terminated
12 enrolled
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Phase 1 Terminated
11 enrolled
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Phase 1 Terminated
12 enrolled
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
KZR-261 in Subjects With Advanced Solid Malignancies
Phase 1 Terminated
61 enrolled 25 charts
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Phase 1 Terminated
3 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of ASP1012 in Adults With Solid Tumors
Phase 1 Terminated
15 enrolled
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase 1 Terminated
65 enrolled 52 charts
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Phase 1 Terminated
75 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Phase 1 Terminated
13 enrolled
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Phase 1 Terminated
44 enrolled
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Phase 1 Terminated
8 enrolled 8 charts
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
AM-003
Phase 1 Terminated
5 enrolled
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Phase 1 Terminated
3 enrolled 9 charts
A Study to Investigate LYL845 in Adults With Solid Tumors
Phase 1 Terminated
39 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Phase 1 Terminated
60 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Phase 1 Terminated
241 enrolled
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Phase 1 Terminated
22 enrolled
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
Phase 1 Terminated
6 enrolled
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
Phase 1 Terminated
7 enrolled
STARLING
Phase 1 Terminated
31 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Photodynamic Therapy-Induced Immune Modulation: Part III
Phase 1 Terminated
12 enrolled 9 charts
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Phase 1 Terminated
6 enrolled
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Phase 1 Terminated
12 enrolled
Dietary Intervention in Patients with a History of Melanoma
Phase 1 Terminated
13 enrolled
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
Phase 1 Terminated
20 enrolled
PANAMA
Phase 1 Terminated
60 enrolled 22 charts
LTbR
Phase 1 Terminated
4 enrolled